STRUCTURE THERAPEUTICS INC. AMERICAN DEPOSITARY SHARES

NASDAQ: GPCR (Structure Therapeutics Inc.)

最近更新时间: 18小时之前

16.13

-0.99 (-5.78%)

前收盘价格 17.12
成交量 786,235
平均成交量 (3个月) 1,176,959
市值 1,154,752,256
股市价格/股市净资产 (P/B) 1.01
52周波幅
16.06 (-0%) — 94.90 (488%)
利润日期 9 Nov 2026
稀释每股收益 (EPS TTM) -3.90
总债务/股东权益 (D/E MRQ) 0.56%
流动比率 (MRQ) 11.90
营业现金流 (OCF TTM) -271.00 M
杠杆自由现金流 (LFCF TTM) -148.98 M
资产报酬率 (ROA TTM) -20.23%
股东权益报酬率 (ROE TTM) -29.51%

AIStockmoo 评分

-0.7
资本回报低于资本成本。资本回报上升。 参考
负债低。盈利能力弱。短期流动性充足。现金流为负。 参考
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
持仓估值 参考 NA
风险溢价 参考 NA
市场估值 参考 NA
过去一年呈下降趋势。股价远低于52周高点。 参考
下降趋势:股价位于均线之下,均线向下。股价已大幅低于均线。下跌日成交量较大。 参考
来自我们对走势图的 AI 技术分析。 参考 NA
K线形态 参考 NA
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻好坏参半或中性。 参考
持仓情绪 参考 NA
机构在最新13F申报中净+5.81%的股份:78家增持,112家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化+1.2%,回补天数6.5天(FINRA)。 参考
内部交易活动 参考 NA
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向不一,评分因此减弱。
每股盈利大多下降。近年曾亏损。 参考
低于中期趋势线。 参考
股价低于其52周平均水平。5年来下跌。 参考
短期动能下降。 参考
支撑与阻力水平趋升。 参考
最终评分 -0.72
全部展开

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看涨
Biotechnology (全球的) 混合的 看涨
股票 Structure Therapeutics Inc. 混合的 看涨

相关股票

股票 市值 DY P/E(TTM) P/B 评分
GPCR 1 B - - 1.01 -0.7
PBLS 3 B - - 3.38 0.8
LEGN 3 B - - 2.59 -1.6
PVLA 2 B - - 10.82 0.9
MAZE 2 B - - 4.13 0.9
IMCR 1 B - - 3.24 -0.2

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

部门 Healthcare
行业 Biotechnology
内部持股比例 3.10%
机构持股比例 97.79%

所有权

姓名 日期 持有股份
Avoro Capital Advisors Llc 30 Sep 2026 6,555,555

该时间范围内无数据。

机构

机构持股比例: 34.48%

持仓变动 机构数 股数
增持 78 16,027,429
减持 112 9,944,170
新建仓 28 8,724,695
清仓 46 2,322,694

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 5,927,622 6.5
15 Oct 2026 7,147,328 4.8
30 Sep 2026 7,540,480 5.2
15 Sep 2026 6,605,011 5.2
31 Aug 2026 5,854,907 7.9
14 Aug 2026 6,079,970 10.4

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

1 正面 1 负面 3 中性
日期 类型 细节
16 Nov 2026 Yahoo Finance Structure Therapeutics (GPCR) Posts Wider Losses, Is The Discount Too Deep?
Structure Therapeutics (GPCR) put its third quarter in focus for investors after reporting a wider net loss of US$144.76 million and a higher loss per share, with year-to-date figures showing a similar pattern. Structure Therapeutics’ share price has fallen sharply over 2026, with a year to date…
13 Nov 2026 Yahoo Finance 4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.
12 Nov 2026 Yahoo Finance Unlearn and Structure Therapeutics Collaborate to Apply AI-Generated Digital Twins in Obesity Research
Retrospective analysis at ObesityWeek® will explore how AI-based modeling can provide context for longer-term obesity study resultsSAN FRANCISCO, CA / ACCESS Newswire / November 12, 2026 / Unlearn today announced a collaboration with Structure Therapeutics Inc., a clinical-stage biopharmaceutical…
09 Nov 2026 Yahoo Finance Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028 Additional aleniglipron data expected in Q4 2026 from supplementary body composition, type 2 diabetes and SWITCH studies…
04 Nov 2026 Yahoo Finance Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced that management will…
27 Oct 2026 Yahoo Finance Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 Earnings
Lilly heads into Q3 earnings with Mounjaro, Zepbound and new drugs fueling growth, but pricing pressure, rising costs and competition pose challenges.
21 Oct 2026 Yahoo Finance How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth.
19 Oct 2026 Yahoo Finance Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming…
19 Oct 2026 Yahoo Finance How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
LLY's surging Mounjaro and Zepbound sales, alongside Foundayo's expanding market access, strengthen its GLP-1 growth momentum ahead of Q3 results.
16 Oct 2026 Yahoo Finance Structure Therapeutics (GPCR) Stock May Be A Bargain Given Its Asset Base
Structure Therapeutics has seen a sharp reset in market sentiment this year, which puts fresh focus on whether the current share price lines up with what its balance sheet can support. With the stock under pressure, the central question is how that drop squares with its book value. Year to date…
12 Oct 2026 Yahoo Finance Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.
08 Oct 2026 Yahoo Finance LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
LLY's recent dip reflects valuation and competition concerns, but strong GLP-1 demand, pipeline growth and diversification support its long-term outlook.
30 Sep 2026 Yahoo Finance Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.
23 Sep 2026 Yahoo Finance Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1…
22 Sep 2026 Yahoo Finance Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger.
22 Sep 2026 Yahoo Finance Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus
Structure Therapeutics (GPCR) has put fresh clinical data for its oral obesity pipeline in front of investors, highlighting results from early stage ACCG-2671 studies and longer term aleniglipron weight loss trials. Recent trading tells a mixed story for Structure Therapeutics. The 1-day share…
22 Sep 2026 Yahoo Finance VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions.
显示更多

技术形态 中期

趋势排列
斜率
入场位置 –
成交量
下降趋势:股价位于均线之下,均线向下。股价已大幅低于均线。下跌日成交量较大。
最近阻力: 18.35 – 19.05 · 中等

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

风险 / 回报
TP1:
TP2:

以入场价计算,止损的亏损相对每个目标价的盈利。通常追求 2 或以上的比率。

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票